15.2 Pediatric Febrile Neutropenia: Risk Stratification, Empiric Antimicrobials & Sepsis Vigilance

Pediatric Fever and Neutropenia

Quick answer: Evaluate fever during cancer therapy or after hematopoietic cell transplantation urgently. Assess perfusion, culture every central-line lumen, and start prompt empiric antibiotics when febrile neutropenia is suspected. Treat clinical instability immediately while collecting cultures and resuscitating. Use a validated pediatric risk strategy for disposition. Persistent fever requires reassessment for a source and a separate assessment of invasive fungal risk.

Recognize the presentation and calculate ANC

U.S. pathways commonly define fever as a temperature of at least 38.3 °C once or 38.0 °C sustained for at least an hour. Severe neutropenia is an absolute neutrophil count (ANC) below 500/µL. Some local febrile-neutropenia pathways include exactly 500/µL. The pathway may also include a child with ANC below 1,000/µL expected to fall to 500/µL or less within 48 hours. Thresholds and measurement routes vary by institution and treatment protocol. Follow the child's oncology plan. An ill child at risk needs assessment and treatment without waiting for a qualifying fever or a new ANC result.

Calculate ANC by multiplying the WBC by the fraction of segmented neutrophils plus bands. For a WBC of 1,200/µL, 14% segmented neutrophils and 6% bands, the fraction is $(14+6)/100=0.20$, so ANC is 240/µL. The count describes neutropenia severity. Disposition also depends on the underlying disease, treatment phase, expected duration, exam and follow-up. UCSF Benioff pediatric pathway · International pediatric guideline

Inflammatory signs may be muted. Check for respiratory symptoms, oral lesions, line and skin findings, abdominal pain and visible perianal changes. Avoid rectal thermometry, routine digital rectal examination and unnecessary rectal instrumentation during significant neutropenia because of mucosal injury risk. A prospective Australian study of 858 episodes found 111 with bacteremia, 185 with another microbiologically documented infection, 80 with a clinically defined infection and 482 with fever of unknown cause. The chart uses the study's episode counts. A child with no clear source can still have serious infection. IDSA neutropenia guideline · Pediatric risk-rule validation cohort

Initial cultures, therapy and disposition

1. Triage and cultures. Assess appearance, perfusion and organ function immediately. Obtain blood cultures from every central venous catheter lumen and consider a concurrent peripheral culture. Label sites and collect cultures before antibiotics when that will not substantially delay treatment. If simultaneous cultures of comparable blood volume grow the same organism and the line culture turns positive at least two hours earlier, this supports a catheter source. Consider urine testing if a clean-catch specimen is readily available and obtain chest radiography at initial evaluation for respiratory signs or symptoms. Collect other samples according to the presentation.
2. Stable high-risk presentation. Start IV antipseudomonal monotherapy and arrange inpatient treatment. Examples include cefepime, piperacillin–tazobactam or, for selected resistance risks, a carbapenem. For example, a U.S. pathway uses cefepime 50 mg/kg per IV dose every 8 hours, maximum 2 g per dose, with renal adjustment as needed. The standard pediatric label covers age 2 months through 16 years. Select the drug with the oncology team using prior cultures, allergies, organ function and the local antibiogram. Many centers aim to start promptly within 60 minutes. This is an operational target. The guideline directs immediate treatment for instability, and assessment of a stable child can follow the local protocol.
3. Instability or suspected resistant infection. Give antibiotics and resuscitate in parallel. Consider a second anti–Gram-negative agent or a glycopeptide when instability, suspected resistance or local resistance warrants it. Shock with a concerning line site or known MRSA infection can justify early vancomycin. Severe mucositis raises risk of invasive infection and may affect disposition. In an otherwise stable child already receiving cefepime, mucositis alone does not routinely require vancomycin. Suspected typhlitis (neutropenic enterocolitis) with pain or distension needs prompt abdominal evaluation and anaerobic coverage. One approach adds metronidazole to cefepime. Piperacillin–tazobactam or meropenem already provides anaerobic coverage.
4. Selected low-risk presentation. Use the institution's validated pediatric strategy. Consider outpatient care only when the child is stable, follow-up and prompt reassessment are reliable, and oncology supports the plan. Oral therapy can be appropriate when the child can take it reliably and obtain it promptly. Fever with shock, an invasive focal infection or inability to take treatment or return reliably changes disposition. International pediatric guideline · Catheter infection guidance · Children's Mercy antibiotic pathway · U.S. cefepime label · Pediatric time-to-antibiotics study

In a system with intensive care availability, the 2026 pediatric sepsis guideline suggests 10–20 mL/kg crystalloid boluses up to 40–60 mL/kg in the first hour of septic shock, adjusted after each bolus and stopped if shock resolves or fluid overload develops. If a vasoactive infusion is indicated, start epinephrine or norepinephrine through available peripheral access while arranging central access as needed. The guideline sets neither a required fluid threshold for initiation nor a universal preference between the two drugs. 2026 pediatric Surviving Sepsis Campaign

Reassess treatment and persistent fever

• Responding to initial therapy: Stop unnecessary empiric double Gram-negative coverage or glycopeptide therapy after 24–72 hours if there is no microbiologic indication to continue. Review the source, cultures and condition. A stable child with persistent fever alone does not routinely need broader antibacterials. If a persistently febrile child becomes unstable, reassess immediately and broaden for resistant Gram-negative, Gram-positive and anaerobic pathogens, using prior cultures and local guidance.
• Stopping empiric antibacterials: The 2023 international guideline recommends stopping for clinically well high- and low-risk children who have been afebrile for at least 24 hours, have negative blood cultures at 48 hours and show marrow recovery. It conditionally permits stopping in low-risk patients meeting the clinical and culture criteria before marrow recovery. More recent randomized trials studied earlier cessation in selected stable, afebrile high-risk children without documented infection. For high-risk children, apply the treating oncology service's current pathway and monitoring criteria. International pediatric guideline · 2025 pediatric leukemia trial · 2026 Danish pediatric trial

Invasive fungal disease and other opportunistic infection

Fungal risk is distinct from initial antibacterial risk. AML, high-risk ALL, relapsed acute leukemia, prolonged neutropenia, high-dose steroids and selected allogeneic transplant recipients raise concern. For a high-risk child still febrile at or beyond 96 hours despite broad-spectrum antibacterials, obtain lung CT and consider abdominal imaging. Consider omitting routine serum galactomannan for this general prolonged-fever workup and avoid routine blood beta-D-glucan or fungal PCR for this purpose. If imaging shows pulmonary nodules with a surrounding ground-glass halo, investigate invasive mold promptly. This pattern can occur with aspergillosis and other conditions. In a targeted workup, respiratory sampling and Aspergillus testing may help when safe and appropriate.

For prolonged fever in a high-risk patient, use caspofungin or liposomal amphotericin B for empiric antifungal treatment unless a preemptive strategy is chosen. The international guideline allows a preemptive strategy in selected high-risk patients who have not had HCT and are not receiving mold-active prophylaxis. Start antifungal treatment when evaluation suggests invasive fungal disease. Low fungal-risk patients may avoid empiric antifungals. When invasive pulmonary aspergillosis is strongly suspected, start directed therapy promptly while pursuing diagnosis. Voriconazole is a preferred option for Aspergillus when appropriate, with pediatric dosing, interaction review and drug-level monitoring. Liposomal amphotericin B is an alternative. Prior prophylaxis, the possibility of another mold and patient factors influence selection. International pediatric guideline · IDSA aspergillosis guideline

Pneumocystis jirovecii pneumonia (PJP) can cause dry cough, hypoxemia and diffuse bilateral opacities in an immunocompromised child. TMP-SMX is standard prophylaxis in at-risk oncology regimens and first-line therapy for suspected PJP. Treat severe suspected disease promptly while arranging appropriate respiratory diagnosis. Individualize adjunctive steroids for non-HIV oncology patients with infectious disease and critical care input. ECIL prophylaxis guideline · ECIL treatment guideline